Aardvark Therapeutics, Inc.
AARD
$8.22
-$0.30-3.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.42M | 4.73M | 4.46M | 3.70M | 2.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.79M | 15.57M | 12.20M | 9.81M | 7.42M |
| Operating Income | -22.79M | -15.57M | -12.20M | -9.81M | -7.42M |
| Income Before Tax | -20.59M | -13.85M | -11.78M | -9.49M | -7.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.59 | -13.85 | -11.78 | -9.49 | -7.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.59M | -13.85M | -11.78M | -9.49M | -7.21M |
| EBIT | -22.79M | -15.57M | -12.20M | -9.81M | -7.42M |
| EBITDA | -14.53M | -5.09M | -- | -- | -- |
| EPS Basic | -5.13 | -3.49 | -2.97 | -2.39 | -1.82 |
| Normalized Basic EPS | -3.17 | -2.16 | -1.77 | -1.36 | -0.95 |
| EPS Diluted | -5.13 | -3.49 | -2.97 | -2.39 | -1.82 |
| Normalized Diluted EPS | -3.17 | -2.16 | -1.77 | -1.36 | -0.95 |
| Average Basic Shares Outstanding | 15.99M | 15.89M | 15.86M | 15.85M | 15.84M |
| Average Diluted Shares Outstanding | 15.99M | 15.89M | 15.86M | 15.85M | 15.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |